An Observational, Cross-Sectional Survey to Assess PML Risk Awareness and Understanding from Patients’ Perspective and Effectiveness of the Tysabri (Natalizumab) Patient Alert Card in the UK (T-PAC)

First published 12/09/2023

Last updated 12/07/2024

EU PAS number:

EUPAS106690

Study

Finalised

Documents

Study protocol

Initial protocol

GB-TYS-12163 Protocol V2 Final 01Dec2022 Redacted.pdf

English (2.01 MB - PDF)View document

Study results

Study report

GB-TYS-12163 Abstract V2 Final 11Jul2024 Redacted[69].pdf

English (241 KB - PDF)View document

Other information

Secondary tabs